Cefotetan targets human Raf1 kinase inhibitor protein (hRKIP), reducing its binding space with Raf1 kinase. This relieves hRKIP's inhibition of the Ras/Raf1/MEK/ERK signaling pathway, enhancing ERK phosphorylation, and making it useful for studying associated diseases. It is also a broad-spectrum antibacterial agent that disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), used to study bacterial infections in bone, skin, urinary tract, and lower respiratory tract.
- Targets hRKIP to enhance ERK phosphorylation.
- Investigates diseases with dysregulated Ras/Raf1/MEK/ERK signaling.
- Broad-spectrum antibacterial action.
- Disrupts bacterial cell wall synthesis.
- Studies various bacterial infections.